Bigger revenues; smaller losses

Driven by gains in home HD with the System One cycler and the approval of nocturnal home HD, NxStage had higher revenues and smaller losses than expected for 2014—and has plans for an updated HD machine and PD.

Read the full article » | Posted 03-11-2015

Related Articles

• Outset Halts Tablo Sales for Home Use Pending FDA Review of New Features Posted 07-13-2022
• Baxter Showcases Kidney Care Products Posted 06-10-2022
• DaVita and Medtronic to Launch New Kidney Tech Company Posted 06-10-2022
• Outset Tablo Could Boost Use of Home Hemodialysis Posted 05-12-2022